The CCNY-MSKCC team’s objective was to address these issues, by publicly releasing a model that has been trained to detect and localize breast, tested on data from two different clinical sites.

Real-world quality of life (QOL) in patients (pts) with metastatic renal cell carcinoma (mRCC) on active surveillance (AS) in the ODYSSEY prospective observational study.. If you have the appropriate ...

Monroe Capital Corporation (NASDAQ: MRCC) Q1 2025 Earnings Call Transcript May 8, 2025 Operator: Welcome to Monroe Capital Corporation’s First Quarter 2025 Earnings Conference Call. Before we ...

Monroe Capital (MRCC) delivered earnings and revenue surprises of -29.63% and 13.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

NOAA restored funding to the Midwest Regional Climate Center just five days after pulling funding for the Purdue-based program.

Monroe Capital's leverage increased to 1.53 times debt to equity, further exacerbating financial instability. Read why MRCC stock is a Hold.

Monroe Capital Corporation (NASDAQ:MRCC) Q4 2024 Earnings Call Transcript March 3, 2025 Monroe Capital Corporation beats earnings expectations. Reported EPS is $0.29, expectations were $0.28 ...

Updated TIDE-A study findings show that maintenance Bavencio with Inlyta treatment interruption is feasible in patients with metastatic renal cell carcinoma.

Monroe Capital operates as a business development company with a large exposure to real estate related investments. Read why MRCC stock is a Hold.

During a Case-Based Roundtable® event, Daniel J. George, MD and participants discussed combination regimens for intermediate and poor-risk renal cell carcinoma.

Investigators report a survival benefit with primary tumor ablation in patients with mRCC compared with no local treatment.